Large pharmaceutical companies say allowing Medicare to negotiate lower drug prices will stifle innovation in drug development. Read a new op-ed in Harvard Business Review to find out why that’s not so.
The Supreme Court case on calculating Medicare disproportionate share payments has financial implications for hospitals and the Centers for Medicare and Medicaid Services.
